581 related articles for article (PubMed ID: 16771791)
21. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
22. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
23. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
24. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
Urologiia; 2001; (4):26-9. PubMed ID: 11569230
[TBL] [Abstract][Full Text] [Related]
25. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
[TBL] [Abstract][Full Text] [Related]
26. [Monotherapy with antiandrogens for prostatic cancer].
Sander S
Tidsskr Nor Laegeforen; 1999 Apr; 119(10):1451-3. PubMed ID: 10354754
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
28. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
29. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
30. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
[TBL] [Abstract][Full Text] [Related]
31. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
32. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns C; Borchers T; Morris T; Armstrong J;
Prostate Cancer Prostatic Dis; 2005; 8(2):194-200. PubMed ID: 15931272
[TBL] [Abstract][Full Text] [Related]
33. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
Iversen P
Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
[TBL] [Abstract][Full Text] [Related]
34. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
35. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
36. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns CF; Navani S; Armstrong J
Prostate Cancer Prostatic Dis; 2007; 10(1):87-93. PubMed ID: 17102802
[TBL] [Abstract][Full Text] [Related]
37. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
38. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
Van Poppel H; Tyrrell CJ; Haustermans K; Cangh PV; Keuppens F; Colombeau P; Morris T; Garside L
Eur Urol; 2005 May; 47(5):587-92. PubMed ID: 15826748
[TBL] [Abstract][Full Text] [Related]
40. [Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer].
Kotake T; Usami M; Isaka S; Shimazaki J; Oishi K; Yoshida O; Ozono S; Okajima E; Kanetake H; Saitoh Y; Tsukagoshi S; Akaza H; Koiso K; Kameyama S; Honma Y; Aso Y; Nakano E; Okuyama A; Naito S; Kumazawa J; Niitani H; Taguchi T
Hinyokika Kiyo; 1996 Feb; 42(2):143-53. PubMed ID: 8712091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
